PMA device
Gel-One(R)
Seikagaku Corp. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Mar 22, 2011, newest Sep 27, 2016Knee osteoarthritis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
964
Naming "Gel-One"
MAUDE reports
193
Brand "Gel-One", since 2015
PubMed studies
61
Mentioning "Gel-One"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Gel-One(R)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- GEL-ONE(R)PMA supplement
P080020-S020 · Decided Sep 27, 2016 · 179 days after receipt · Panel Track
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Gel-One", any status and sponsor, newest update first.
i+Med S.Coop.Not on our public-company list
NCT07402395 · 40 participants · Start Nov 22, 2024 · Primary completion Sep 2, 2025
Device: BtHIntimate® Injectable Hyaluronic Acid Treatment · For: Vulvar Atrophy
Sites: Madrid, Spain
963 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Gel-One", and for the whole product code for context.
This brand
193 reports: 22 malfunction, 154 injury, 14 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
0001822565-2026-02658 · Received Jul 22, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Pain; Ambulation or Postural Difficulties
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Gel-One"[tiab]. The summary above synthesizes these.
- Bacterial vaginosis.
Wang J · Prim Care Update Ob Gyns · 2000
- Efficacy of In-office Bleaching Gel One Week After Mixing: A Randomized Clinical Trial.
de Freitas IM, Carneiro TS, Forville H, et al. · Oper Dent · 2025Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Two new intra-articular injections for knee osteoarthritis.
Med Lett Drugs Ther · 2018
- A Comprehensive Review of Viscosupplementation in Osteoarthritis of the Knee.
Peck J, Slovek A, Miro P, et al. · Orthop Rev (Pavia) · 2021Review
- Medical management of pediatric glaucoma: lessons learned from randomized clinical trials.
Sacchi M, Lizzio RAU, Villani E, et al. · Graefes Arch Clin Exp Ophthalmol · 2020Systematic Review
- A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid.
Nicholls M, Manjoo A, Shaw P, et al. · Adv Ther · 2018Research Support, Non-U.S. Gov't
- Azelaic acid 15% gel: in the treatment of papulopustular rosacea.
Frampton JE, Wagstaff AJ · Am J Clin Dermatol · 2004Review
- Collagen Hydrogel Loaded With 9-cisRA-Lip Is an Option for Treatment of Secondary Lymphedema after Surgery.
Yao M, Wei J, Chen L, et al. · Cancer Biother Radiopharm · 2025
- Synthesis and Antibacterial Properties of Novel ZnMn2O4-Chitosan Nanocomposites.
Packirisamy RG, Govindasamy C, Sanmugam A, et al. · Nanomaterials (Basel) · 2019
- Silicone gel sheeting for treating hypertrophic scars.
Jiang Q, Chen J, Tian F, et al. · Cochrane Database Syst Rev · 2021Research Support, Non-U.S. Gov't, Systematic Review
- Proteomic Profiling of Human Small Cell Lung Cancer Cell Line NCI-H211.
Cho HY, Kim MK, Yoo YD, et al. · Cancer Res Treat · 2003
- Risk of Severe Acute Localized Reactions for Different Intraarticular Hyaluronic Acid Knee Injections in a Real-World Setting.
Ong KL, Farr J, Gudeman AS, et al. · Cartilage · 2021Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
- Orthovisc Sodium HyaluronateAnika Therapeutics, Inc. · PMA 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.